➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
McKesson
Moodys
Baxter

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Acalabrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02029443 ↗ ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1/Phase 2 2014-01-01 This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02157324 ↗ Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia Active, not recruiting Acerta Pharma BV Phase 1 2014-08-01 This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711 ↗ An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma Active, not recruiting Acerta Pharma, LLC Phase 1 2014-07-01 To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02180711 ↗ An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma Active, not recruiting Acerta Pharma BV Phase 1 2014-07-01 To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02211014 ↗ An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Active, not recruiting Acerta Pharma, LLC Phase 1 2015-02-01 To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
NCT02211014 ↗ An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma Active, not recruiting Acerta Pharma BV Phase 1 2015-02-01 To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
NCT02213926 ↗ An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Active, not recruiting Acerta Pharma BV Phase 2 2014-09-01 The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acalabrutinib

Condition Name

Condition Name for Acalabrutinib
Intervention Trials
Chronic Lymphocytic Leukemia 21
Mantle Cell Lymphoma 15
Small Lymphocytic Lymphoma 7
Diffuse Large B Cell Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acalabrutinib
Intervention Trials
Lymphoma 46
Leukemia, Lymphocytic, Chronic, B-Cell 30
Leukemia, Lymphoid 28
Leukemia 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acalabrutinib

Trials by Country

Trials by Country for Acalabrutinib
Location Trials
United States 138
United Kingdom 7
Poland 6
Canada 5
Italy 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acalabrutinib
Location Trials
Texas 14
Ohio 12
California 11
Washington 11
New York 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 89
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase Trials
Not yet recruiting 64
Recruiting 20
Active, not recruiting 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Sponsor Name for Acalabrutinib
Sponsor Trials
AstraZeneca 34
Acerta Pharma BV 33
National Cancer Institute (NCI) 16
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acalabrutinib
Sponsor Trials
Industry 81
Other 73
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
AstraZeneca
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.